- Healthcare artificial intelligence company Decode Health will partner with Quest Diagnostics ( NYSE: DGX ) on using biomarker-based data to cut the time and cost of developing novel diagnostic tests and identifying new drug targets .
- Both companies have developed a platform for collecting and storing de-identified specimens from individuals participating in research sponsored by pharmaceutical companies as well as research organizations.
- Quest Diagnostics ( DGX ) and Decode will share in any outcomes from any data licensing, biomarker discovery or diagnostics development that occurs.
- Read why Seeking Alpha contributor Biologics is very bullish on Quest Diagnostics ( DGX ).
For further details see:
Decode Health, Quest to collaborate to improve biomarker discovery for drug discovery